
|Videos|November 12, 2021
ImprimisRx President John Saharek discusses 3 new products in the pipeline
Author(s)David Hutton, Modern Retina Staff
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
Advertisement
John Saharek, president of ImprimisRX, speaks with Modern Retina's David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting, including:
- Moxi-Brom (moxifloxacin hydrochloride 0.5% and bromfenac sodium sesquihydrate 0.075%)
- Klarity-CL drops (cyclosporine 0.1% / loteprednol etabonate 0.2% ophthalmic suspension)
- Tim-Brim-Dor-Bim (prednisolone acetate 1%, gatifloxacin 0.5%, bromfenac 0.075%).
The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.
Related Content:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
2
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











